Vaginal Estrogen in Breast Cancer Survivors: What the Evidence Shows on Safety
Synthesising evidence from 10+ observational studies, systematic reviews, meta-analyses, and the landmark 2025 FDA label change on the safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- The largest available meta-analysis (Beste et al., AJOG 2025) found that vaginal estrogen in breast cancer survivors was not associated with increased breast cancer recurrence, breast cancer-specific mortality, or overall mortality — consolidating the safety signal from multiple prior observational studies.
- A population-based cohort study of 49,237 women with breast cancer (McVicker et al., JAMA Oncol 2024) found no evidence of increased breast cancer-specific mortality with vaginal estrogen therapy use, and one formulation (vaginal estriol) was associated with a mortality reduction (HR 0.77, 95% CI 0.63–0.94).
- In November 2025, the FDA removed the boxed warning linking vaginal estrogen to breast cancer risk, recognising that topical vaginal formulations have a distinct safety profile from systemic hormone therapy — a change endorsed by ACOG and major menopause societies.
- Uncertainty persists specifically for women on concurrent aromatase inhibitors, where small studies have shown transient serum estradiol elevations with vaginal estradiol (but not estriol or prasterone), and no RCT has assessed oncological safety in this subgroup.
Why This Topic Matters
Over 70% of postmenopausal breast cancer survivors experience genitourinary syndrome of menopause (GSM) — a progressive condition encompassing vulvovaginal dryness, burning, dyspareunia, urinary urgency, and recurrent urinary tract infections. The incidence of GSM is approximately 20% higher in breast cancer survivors than in postmenopausal women without cancer, and symptoms are significantly exacerbated by adjuvant endocrine therapies, particularly aromatase inhibitors (AIs).
Despite vaginal estrogen being first-line treatment for GSM in the general postmenopausal population, clinicians have been reluctant to prescribe it to breast cancer survivors — driven by the FDA’s former boxed warning and oncological concerns about systemic estrogen absorption. This reluctance has created a major treatment gap: data suggest that fewer than 5% of eligible breast cancer survivors with GSM are prescribed vaginal estrogen, even when non-hormonal alternatives have failed. The clinical consequence is significant — untreated GSM reduces quality of life, impairs sexual function, and may contribute to non-adherence to adjuvant endocrine therapies.
What Evidence Was Reviewed
This synthesis draws on two recent systematic reviews and meta-analyses (Beste et al. 2025; Santos et al. 2025), a large population-based cohort study (McVicker et al. 2024), a retrospective safety study (Agrawal et al. 2023), a meta-analysis of serum estradiol levels with vaginal estrogen formulations (Comini et al. 2023), NAMS/ISSWSH consensus recommendations (2018), the 2022 NAMS Hormone Therapy Position Statement, the 2025 AUA/SUFU/AUGS GSM guideline, and the 2025 FDA regulatory action. Evidence is current through April 2026.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Beste et al. (AJOG 2025) | SR/MA | ~56,000 | BC survivors using VET | No increased recurrence (pooled OR across studies), no increased BC-specific or overall mortality | High |
| Santos et al. (2025) | SR/MA of 7 studies | NR | BC survivors using VET | No increased risk of recurrence or mortality; consistent across formulations | Moderate |
| McVicker et al. (JAMA Oncol 2024) | Population cohort | 49,237 | BC patients, Scotland/Wales | No increased BC-specific mortality; vaginal estriol associated with reduced mortality (HR 0.77, 95% CI 0.63–0.94) | High |
| Agrawal et al. (Obstet Gynecol 2023) | Retrospective cohort | NR | BC survivors with GSM | No increased recurrence with vaginal estrogen use | Moderate |
| Comini et al. (Clin Breast Cancer 2023) | SR/MA | NR | BC survivors, serum E2 focus | Low-dose vaginal estrogen associated with minimal systemic absorption; serum E2 remained within postmenopausal range | Moderate |
| Crandall et al. (WHI, Menopause 2018) | Observational (WHI) | ~45,000 | Postmenopausal women | No increased invasive BC incidence with VET after 6.4 years follow-up | High |
| Le Ray et al. (2012) | Nested case-control | 13,479 | BC survivors on tamoxifen | No increased recurrence with local estrogen therapy among tamoxifen-treated women | Moderate |
| Kendall et al. (Ann Oncol 2006) | Observational | 6 | BC survivors on AIs | Vaginal estradiol raised serum E2 above postmenopausal range in women on AIs | Low |
| NAMS/ISSWSH Consensus (2018) | Expert consensus | NR | BC survivors/high-risk | Local hormone therapy may be considered when non-hormone treatments fail, with oncologist consultation | Guideline |
| FDA Label Change (2025) | Regulatory action | NR | All vaginal estrogen products | Removed boxed warning for breast cancer; acknowledged distinct safety profile from systemic HT | Regulatory |
Key Findings on Vaginal Estrogen Safety in Breast Cancer Survivors
Recurrence and Mortality: Reassuring Signal Across Multiple Studies
The central safety question — whether vaginal estrogen increases the risk of breast cancer recurrence or death — has now been addressed by multiple large observational studies and two systematic reviews with meta-analysis. The Beste et al. meta-analysis (AJOG 2025) pooled data from studies encompassing tens of thousands of breast cancer survivors and found no statistically significant increase in breast cancer recurrence, breast cancer-specific mortality, or overall mortality with vaginal estrogen therapy use.
The McVicker cohort study, published in JAMA Oncology in 2024, analysed 49,237 women with newly diagnosed breast cancer across Scotland and Wales. After adjusting for tumour characteristics, treatment, and comorbidities, vaginal estrogen use was not associated with higher breast cancer-specific mortality compared with no hormone replacement therapy. For one specific formulation — vaginal estriol (0.03 mg) — a statistically significant mortality reduction was observed (HR 0.77, 95% CI 0.63–0.94), an intriguing finding that the authors attributed in part to the lower potency of estriol relative to estradiol and possible confounding by indication.
Systemic Absorption: Minimal With Low-Dose Formulations
The biological basis for concern about vaginal estrogen has always been the potential for systemic estrogen absorption — theoretically stimulating oestrogen-receptor-positive tumour cells. The Comini et al. meta-analysis of serum estradiol levels in breast cancer survivors using various vaginal estrogen formulations found that low-dose preparations consistently maintained serum estradiol within the normal postmenopausal range. Mitchell and colleagues, in a secondary analysis of an RCT, confirmed that vaginal estradiol tablets did not significantly raise serum estrogen levels beyond postmenopausal values in most women.
An important caveat, however, emerged from the Kendall et al. study and subsequent research on women concurrently taking aromatase inhibitors. Because AIs suppress circulating estradiol to extremely low levels (often below 5 pmol/L), even the small amount of estradiol absorbed from vaginal preparations can produce a proportionally larger relative increase, potentially counteracting the AI’s therapeutic effect. This pharmacological interaction represents the most clinically relevant area of ongoing concern, though no study has demonstrated that these transient elevations translate into worse oncological outcomes.
The Regulatory Shift: FDA Removes Boxed Warning
In November 2025, the FDA removed the boxed warning related to breast cancer from all vaginal estrogen products, as part of a broader label revision for menopausal hormone therapy products. The agency acknowledged that vaginal estrogen formulations have a safety profile distinct from systemic hormone therapy, with minimal systemic absorption and no demonstrated increase in breast cancer incidence. This regulatory action aligned with positions already held by ACOG, NAMS, and major international menopause societies, and was widely endorsed by the obstetric and gynaecological community.
Women taking AIs represent the subgroup with the greatest theoretical concern. AIs suppress peripheral aromatisation to achieve estradiol levels well below those of natural menopause, and any exogenous estrogen absorption could, in theory, undermine this therapeutic suppression. The Kendall et al. study (2006) demonstrated that vaginal estradiol (25 mcg tablets) raised serum estradiol above postmenopausal thresholds in some women on AIs, while the Streff et al. study (2021) showed that the vaginal estradiol ring (Estring, 2 mg/90 days) produced variable serum estradiol changes in AI-treated women.
However, no study to date has demonstrated that these serum elevations translate into increased cancer recurrence or mortality. The Le Ray et al. nested case-control study found no increased recurrence risk with local estrogen therapy among tamoxifen-treated patients, though data specifically in AI-treated populations remain limited. The NAMS/ISSWSH consensus and ASCO guidelines suggest that if vaginal hormone therapy is considered for AI-treated patients, vaginal DHEA (prasterone) or ultra-low-dose estriol may be preferable to estradiol-based products, though comparative safety data in this specific population are insufficient.
Not all vaginal estrogen formulations carry equivalent systemic absorption profiles. Estradiol (the most potent natural estrogen) is available as vaginal tablets (10 mcg), cream, and a vaginal ring. Estriol (a weaker estrogen with primarily local effects) is widely used in Europe and parts of Asia. Prasterone (vaginal DHEA) is converted locally to androgens and estrogens via intracellular enzymes.
The McVicker study’s finding of a possible mortality reduction with vaginal estriol (HR 0.77) is consistent with estriol’s lower systemic potency and may support its preferential use in breast cancer survivors, though this finding is observational and potentially subject to confounding. The Comini meta-analysis found that estriol-based formulations produced the smallest serum estradiol changes. Prasterone has the advantage of being locally converted — meaning serum estradiol levels are generally not affected — but FDA labelling still carries warnings for breast cancer patients, and safety data specifically in this population are sparse. Ultra-low-dose estriol vaginal gel (0.005%) has been studied in a phase II RCT in AI-treated women and showed symptom improvement without significant serum estradiol elevation.
The distinction between ER-positive and ER-negative (including triple-negative) breast cancers is critical for risk stratification in vaginal estrogen prescribing. Women with triple-negative breast cancer (TNBC) lack estrogen receptor expression, meaning that any systemic estrogen absorbed from vaginal preparations would have no biological mechanism to stimulate tumour growth. The NAMS/ISSWSH consensus explicitly noted that the risk–benefit calculus differs substantially between these subtypes.
For women with ER-positive cancers, the primary concern is the potential for exogenous estrogen to activate residual or dormant tumour cells. However, no study has demonstrated differential recurrence rates with vaginal estrogen by receptor status, largely because available studies are underpowered for subgroup analyses. The clinical approach recommended by NAMS/ISSWSH is to consider vaginal estrogen more readily in TNBC survivors (where theoretical risk is absent) and to engage in more cautious shared decision-making with oncologists for ER-positive cancer survivors, particularly those on active endocrine therapy.
Current guidelines unanimously recommend non-hormonal treatments as first-line therapy for GSM in breast cancer survivors. These include vaginal moisturisers (applied regularly to hydrate tissue), lubricants (used during intercourse), and physical therapy for pelvic floor dysfunction. The 2025 AUA/SUFU/AUGS guideline additionally acknowledges emerging evidence for vaginal laser therapy (CO₂ and erbium), though long-term safety and efficacy data are limited and this intervention is not FDA-approved for GSM.
When non-hormonal approaches are insufficient — which occurs frequently, as GSM is progressive and many women require more than moisturisation — the stepped approach recommended by NAMS/ISSWSH involves a shared decision-making discussion with the patient’s oncologist before initiating low-dose vaginal hormone therapy. The conversation should address the severity of symptoms, impact on quality of life, breast cancer subtype, current endocrine therapy, time since diagnosis, and the patient’s own values regarding the risk–benefit balance. Ospemifene (a selective estrogen receptor modulator) is an FDA-approved oral alternative for dyspareunia that does not appear to increase breast cancer risk, though it carries a theoretical concern in ER-positive disease and is not recommended by all guidelines in this population.
Quality & Consistency of Evidence
What the Evidence Does Not Show
No randomised controlled trial has assessed oncological outcomes (recurrence, mortality) with vaginal estrogen in breast cancer survivors. The ethical and logistical barriers to conducting such a trial — given the large sample sizes and long follow-up required — make it unlikely that RCT evidence will emerge. All current evidence derives from observational studies subject to healthy-user bias, confounding by indication, and selection bias.
The safety of vaginal estrogen specifically in women on concurrent aromatase inhibitors remains the most important unresolved question. The small pharmacokinetic studies showing serum estradiol elevations with vaginal estradiol in this population have not been linked to clinical outcomes, but the theoretical concern is biologically plausible and no adequately powered observational study has isolated this subgroup.
Comparative data between vaginal estrogen formulations (estradiol tablets vs. cream vs. ring vs. estriol vs. prasterone) in breast cancer survivors are absent. Which formulation offers the optimal balance of GSM symptom relief with minimal systemic absorption for this population cannot be determined from the available evidence. Additionally, long-term safety data beyond 5–10 years are unavailable from any study in this specific population.
Practical Implications
Based on the current evidence, the following considerations may inform clinical decision-making for breast cancer survivors with GSM.
Non-hormonal therapies (moisturisers, lubricants, pelvic floor therapy) remain first-line. When these are insufficient — which occurs frequently given the progressive nature of GSM — low-dose vaginal estrogen may be considered through shared decision-making with the patient’s oncologist, consistent with NAMS/ISSWSH and AUA/SUFU/AUGS guideline recommendations.
Multiple observational studies and two meta-analyses find no association between vaginal estrogen and breast cancer recurrence or mortality. The 2025 FDA label change formally recognised this evidence. These data may support more confident prescribing when non-hormonal options have failed.
For breast cancer survivors on aromatase inhibitors, vaginal estriol or prasterone (DHEA) may be preferable to vaginal estradiol based on pharmacokinetic data showing lower systemic absorption. Ultra-low-dose formulations should be selected. However, comparative oncological outcome data do not exist for any formulation in this specific subgroup.
GSM is substantially underdiagnosed and undertreated in breast cancer survivors. Clinicians should proactively inquire about vulvovaginal and urinary symptoms during follow-up, as patients may not spontaneously report these concerns. Early identification allows initiation of non-hormonal management before symptoms become severe.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate (No Increased Oncological Risk) / Limited (AI-Specific Safety)
For the question of whether vaginal estrogen increases breast cancer recurrence or mortality, the evidence is moderate-certainty and consistently reassuring across multiple observational studies and meta-analyses. For the specific question of safety in women on concurrent aromatase inhibitors, evidence remains limited and the pharmacokinetic concerns have not been resolved by outcome data.
- Vaginal estrogen therapy for GSM in breast cancer survivors is not associated with increased breast cancer recurrence, breast cancer-specific mortality, or overall mortality based on the best available observational evidence and meta-analyses.
- The FDA’s 2025 removal of the breast cancer boxed warning from vaginal estrogen products reflects the accumulated evidence that topical vaginal formulations have a distinct and reassuring safety profile compared with systemic hormone therapy.
- Non-hormonal treatments remain first-line for GSM in breast cancer survivors, but when these fail, low-dose vaginal estrogen should be discussed as an option through shared decision-making with the patient and her oncologist.
- For women on concurrent aromatase inhibitors, lower-potency formulations (vaginal estriol, prasterone) may be preferable to vaginal estradiol, though comparative oncological outcome data are not available for any formulation in this specific population.
- The absence of RCT evidence and formulation-specific comparative data in breast cancer survivors represents the most significant remaining limitation — these gaps are unlikely to be addressed by randomised trials given ethical and practical constraints.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2025;232(3):262-270.e1. DOI: 10.1016/j.ajog.2024.10.054
- McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-108. DOI: 10.1001/jamaoncol.2023.4508
- Agrawal P, Singh SM, Able C, et al. Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. Obstet Gynecol. 2023;142(3):660-668. DOI: 10.1097/AOG.0000000000005294
- Santos GML, Magalhães AO, Teichmann PV, et al. Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis. Rev Bras Ginecol Obstet. 2025;47:e-rbgo46. DOI: 10.61622/rbgo/2025rbgo46
- Comini AC, Carvalho BM, Moreira MJ, et al. Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer. 2023;23(8):835-846. DOI: 10.1016/j.clbc.2023.08.003
- Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596-608. DOI: 10.1097/GME.0000000000001121
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. DOI: 10.1097/GME.0000000000002028
- Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20. DOI: 10.1097/GME.0000000000000956
- Le Ray I, Dell’Aniello S, Bhonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603-609. DOI: 10.1007/s10549-012-2198-y
- Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-587. DOI: 10.1093/annonc/mdj127
- Mitchell CM, Larson JC, Crandall CJ, et al. Association of vaginal estradiol tablet with serum estrogen levels in women who are postmenopausal: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241743. DOI: 10.1001/jamanetworkopen.2022.41743
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Published November 10, 2025. Available at: fda.gov
- Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol. 2022;13(2):71-100. DOI: 10.5306/wjco.v13.i2.71